BioSpace News Archive

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report third quarter financial results on Monday, November 8, 2021, after market close.

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 third quarter on Thursday, November 11, 2021 before the open of the U.S. financial markets.

The Muscular Dystrophy Association announced the awarding of 18 new MDA grants totaling over $1.6 million toward neuromuscular disease research.

Global health service company Cigna Corporation announced that Brian Evanko, executive vice president and chief financial officer, will present at the Wolfe Research Virtual Healthcare Conference on November 18, 2021 through a virtual webcast.

OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced financial results for the quarter ended September 30, 2021.

“Brilliant workflows. Made for you.” is the key theme for international medical imaging IT and cybersecurity company Sectra in booth #8115 at the Radiological Society of North America 2021 Annual Meeting.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) today announced its EsoGuard® Esophageal DNA Test has been selected as winner of the “Diagnostics Innovation of the Year” award in the inaugural awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present abstracts at the American Society of Nephrology (ASN) Kidney Week 2021, which is being held virtually from November 4-7, 2021.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Bernadette Connaughton to its Board of Directors.

HanAll Biopharma (KRX: 009420.KS) announced today that the company had achieved sales of 25.5 billion won, an operating profit of 2.2 billion won, and a net profit of 2.1 billion won in the third quarter of 2021.